Katsuhiro Miura

Director
Department of Hematology and Oncology, Nihon University Itabashi Hospital
Tokyo, Tokyo, Japan

Presentation(s):

• LB 01.1 - Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study

  Sunday, June 23, 2024
  09:30 – 09:45 ICT